Top Markets
#1 FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock) +17.95%
#2 clBTC clBTC +12.15%
#3 OpenEden OpenEden +11.48%
#4 BasedHype BasedHype +11.14%
#5 Wrapped Ether (Mantle Bridge) Wrapped Ether (Mantle Bridge) +8.73%
#6 Not in Employment, Education, or Training Not in Employment, Education, or Training +8.41%
#7 Mantle Staked Ether Mantle Staked Ether +8.34%
#8 Mantle Restaked ETH Mantle Restaked ETH +8.01%
#9 MarsCoin MarsCoin +6.65%
#10 EfficientFrontier EfficientFrontier +4.93%
Coin of the day
FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock)
Settings
Language
ENGLISH
Currency
USD
Theme
NeonMind Biosciences Inc. NeonMind Biosciences Inc.

NeonMind Biosciences Inc.

NMDBF
Rank in Stocks #40197
NeonMind Biosciences Inc. specializes in the research, formulation, and... NeonMind Biosciences Inc. specializes in the research, formulation, and commercialization of medicinal and psychedelic fungi aimed at treating mental health conditions. The company is actively developing a line of psilocybin-derived products, featuring various mushroom-infused preparations, specifically tailored for weight loss and management. Originally incorporated in 2019 as Flourish Mushroom Labs Inc., it rebranded to NeonMind Biosciences Inc. in April 2020. Headquartered in Oakville, Canada, the company operates as a subsidiary of The Yield Growth Corp.
Share Price
$0.228
Last synced: 2023-05-23
Market Cap
$213.62K
Change (1 day)
0.00%
Change (1 year)
0.00%
Country
CA
Trade NeonMind Biosciences Inc. (NMDBF)

Category

Healthcare
Revenue for NeonMind Biosciences Inc. (NMDBF)
Revenue in Aug 2026 TTM: 0
According to NeonMind Biosciences Inc. latest financial reports the company's current revenue (TTM) is 0. In 2026 the company made a revenue of 0 equal to the revenue in the year 2026 that was 0. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history for NeonMind Biosciences Inc. from 2026 to 2026
Revenue at the end of each year
Year Revenue Change
Not enough data for the provided dates.
Revenue for similar companies or competitors
Company Revenue Revenue Difference Country
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $12.62B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $6.02B -
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
 - -
KR
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
 $10.11B -
BE